You are now leaving BIKTARVY.com.
By following this link, you are now leaving BIKTARVY.com. This site is not controlled by Gilead Sciences, Inc. Gilead Sciences, Inc. is not responsible for the site's content or your use of the site.
During this time, Gilead is committed to helping those living with HIV have access to their medications. If you need support affording your medicine, we may be able to help. Get Financial Support
The most common side effects of BIKTARVY in clinical studies through 3 years were each experienced in at least 5% of people.
In clinical studies of 634 adults new to HIV-1 treatment, the most common side effects were diarrhea (6%), nausea (6%), and headache (5%).
These are not the only side effects of BIKTARVY. Tell your healthcare provider if you have any side effects that bother you or do not go away.
BIKTARVY was evaluated in 4 clinical trials, involving more than 2,400 adults living with HIV.
Results showed that BIKTARVY works in a diverse group of adults, regardless of age, sex, race, viral load, or CD4 T-cell count.
of adults new to treatment stopped taking BIKTARVY because of side effects
vs 2% of adults who stopped taking either one of the other treatments due to side effects.*
*The other treatments were TRIUMEQ® (abacavir, dolutegravir, lamivudine) or DESCOVY® (emtricitabine, tenofovir alafenamide) + TIVICAY® (dolutegravir).
†The continued treatments were TRIUMEQ (abacavir, dolutegravir, lamivudine) or a combination of either EPZICOM® (abacavir, lamivudine) or TRUVADA® (emtricitabine, tenofovir disoproxil fumarate) + atazanavir or darunavir (with cobicistat or ritonavir).